Clinical Trial Update: A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia [Phase 3]

View source ↗

Summary

Phase III, multicenter, double-blind, placebo-controlled withdrawal study in patients with hyperphosphatemia related to chronic kidney disease; the trial has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Chronic Kidney Disease, Hyperphosphatemia | Phase 3 | Status: COMPLETED | Results posted: 2014-10-23